Compare RDW & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDW | XNCR |
|---|---|---|
| Founded | 2020 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | RDW | XNCR |
|---|---|---|
| Price | $10.21 | $12.93 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 10 |
| Target Price | $12.67 | ★ $22.78 |
| AVG Volume (30 Days) | ★ 23.0M | 806.0K |
| Earning Date | 03-09-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $296,147,000.00 | $150,132,000.00 |
| Revenue This Year | $11.62 | $18.68 |
| Revenue Next Year | $41.41 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 38.16 |
| 52 Week Low | $4.87 | $6.92 |
| 52 Week High | $26.66 | $21.00 |
| Indicator | RDW | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.69 | 36.97 |
| Support Level | $9.67 | $12.41 |
| Resistance Level | $12.46 | $15.40 |
| Average True Range (ATR) | 1.24 | 0.80 |
| MACD | 0.02 | -0.18 |
| Stochastic Oscillator | 55.36 | 20.10 |
Redwire Corp is engaged in mission-critical space solutions and reliable components for the next-generation space economy. It assists its customers in solving the complex challenges of future space missions and industries. The company's space infrastructure offerings include a broad array of modern products and services, which have been enabling space missions. The company's plan enables it to combine decades of flight heritage with a culture creating new technologies that are the building blocks of space infrastructure for government and commercial customers.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.